Johnson & Johnson JNJ
Johnson & Johnson is a multinational pharmaceutical and medical devices company that develops, manufactures, and sells health products worldwide. Johnson & Johnson shows solid financial health (ND/EBITDA 0.81) and high quality (ROE 25.74%), but its valuation is demanding (P/E 31.46) and earnings growth is flat (-0.90%), limiting short-term appeal.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Johnson & Johnson is a multinational pharmaceutical and medical devices company that develops, manufactures, and sells health products worldwide. Johnson & Johnson shows solid financial health (ND/EBITDA 0.81) and high quality (ROE 25.74%), but its valuation is demanding (P/E 31.46) and earnings growth is flat (-0.90%), limiting short-term appeal.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.4 |
| Quality / Moat | 7.9 |
| Valuation | 3.8 |
| Growth | 5.1 |
| Dividend | 6.4 |
| Momentum | 8.6 |
| Risk & Context | 8.6 |
OVERALL SCORE: 6.7/10
Context and risks
JNJ operates in the US pharmaceutical sector, subject to regulatory pressure on drug prices (IRA) and a litigation environment over talc. The country's governance/regulatory risk is reflected in a moderate penalty.
News considered in the analysis
- Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification? — Comparativa genérica entre dos farmacéuticas sin información nueva sobre JNJ.
- Want Bulletproof Dividend Income? These 3 Stocks Have Raised Payouts Through 8 Major Downturns — Listículo sobre dividendos; no aporta información nueva sobre la empresa.
- What Does Johnson & Johnson (JNJ) New Clinical Data Mean For Its Stock? — Datos clínicos nuevos pueden afectar el pipeline, pero el impacto es incierto y probablemente ya parcialmente descontado.
- AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? — Comparativa de análisis sin información nueva material.
- Is LLY Stock Cheaper Than It Looks? — Artículo sobre Lilly, no sobre JNJ; irrelevante.
Verdict: Hold; quality and balance sheet are solid, but valuation offers no margin of safety.
Main risk: The main risk is US drug pricing regulatory pressure and pending talc litigation, which could impact margins and reputation.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →